Citation : Konstantina Mitrousi, Gregory Y H Lip, Stavros Apostolakis
For many years, vitamin K antagonists were the only approved anticoagulants for the management of atrial fibrillation. Lately new anticoagulants made their appearance and large trials have already shown their superiority against vitamin K antagonists. Since the arrhythmia is encountered frequently in the elderly, it is crucial to identify the beneficial effects of the novel oral anticoagulants in this particular patient population.
Atrial fibrillation is associated with significant morbidity and mortality. There is a strong relationship between atrial fibrillation and aging, thromboembolism, stroke, congestive heart failure and hypertension. In addition, advanced age is a powerful risk factor for stroke and thromboembolism in patients with atrial fibrillation.
For many years, vitamin K antagonists were the only approved anticoagulants for the management of atrial fibrillation. Lately new anticoagulants made their appearance and large trials have already shown their superiority against vitamin K antagonists. Since the arrhythmia is encountered frequently in the elderly, it is crucial to identify the beneficial effects of the novel oral anticoagulants in this particular patient population.
No comments:
Post a Comment